Niagen Bioscience: Strengthened NR Patent Control and Differentiated Efficacy Support Buy Rating and $14 Target

Niagen Bioscience, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Susan Anderson from Canaccord Genuity maintained a Buy rating on the stock and has a $14.00 price target.

Susan Anderson has given his Buy rating due to a combination of factors tied to Niagen Bioscience’s strengthening competitive position and intellectual property. She sees the newly acquired portfolio of nicotinamide riboside (NR) and related salt-form patents as a meaningful expansion of the company’s ownership over its core technology, shifting Niagen from a shared-ownership structure with Queen’s University Belfast to full control of these key assets. In her view, this enhances the company’s ability to enforce its rights, counter infringement, and respond to misleading competitive claims in the NR and NAD+ space, which should support the long‑term value of the TruNiagen franchise.
Susan Anderson’s rating is based on the belief that Niagen is well positioned to capitalize on the growing consumer and scientific interest in healthy aging and NAD+ supplementation. She emphasizes that Niagen’s proprietary NR ingredient appears, based on management commentary and published research, to be more effective at elevating NAD+ levels than alternative precursors such as NMN, primarily due to better cellular uptake. Even as regulatory stances on competing ingredients like NMN evolve, she expects Niagen’s enhanced patent protection and differentiated efficacy profile to reinforce its competitive moat. Taken together, these dynamics underpin her view that the company has attractive long‑term growth prospects, supporting a Buy rating and her $14 price target.

According to TipRanks, Anderson is a 5-star analyst with an average return of 17.6% and a 44.24% success rate. Anderson covers the Consumer Cyclical sector, focusing on stocks such as Ulta Beauty, Sally Beauty, and Peloton Interactive.

In another report released on December 9, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $7.00 price target.